112 related articles for article (PubMed ID: 16334164)
1. Reduced alpha- and beta-catenin expression predicts shortened survival in local prostate cancer.
Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
Anticancer Res; 2005; 25(6C):4707-12. PubMed ID: 16334164
[TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.
Kärjä V; Aaltomaa S; Lipponen P; Isotalo T; Talja M; Mokka R
Anticancer Res; 2005; 25(6C):4435-8. PubMed ID: 16334122
[TBL] [Abstract][Full Text] [Related]
4. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
5. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Kosma VM
Br J Cancer; 1999 May; 80(3-4):477-82. PubMed ID: 10408856
[TBL] [Abstract][Full Text] [Related]
6. The expression and prognostic value of alpha-, beta- and gamma-catenins in renal cell carcinoma.
Aaltomaa S; Lipponen P; Kärjä V; Lundstedt S; Lappi J; Kosma VM
Anticancer Res; 2004; 24(4):2407-13. PubMed ID: 15330191
[TBL] [Abstract][Full Text] [Related]
7. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer.
Yip PY; Kench JG; Rasiah KK; Benito RP; Lee CS; Stricker PD; Henshall SM; Sutherland RL; Horvath LG
Prostate; 2011 Nov; 71(15):1638-45. PubMed ID: 21432866
[TBL] [Abstract][Full Text] [Related]
8. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
[TBL] [Abstract][Full Text] [Related]
10. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence.
Li H; Zhang Y; Glass A; Zellweger T; Gehan E; Bubendorf L; Gelmann EP; Nevalainen MT
Clin Cancer Res; 2005 Aug; 11(16):5863-8. PubMed ID: 16115927
[TBL] [Abstract][Full Text] [Related]
11. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.
Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM
BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880
[TBL] [Abstract][Full Text] [Related]
12. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
Tollefson MK; Leibovich BC; Slezak JM; Zincke H; Blute ML
J Urol; 2006 Feb; 175(2):547-51. PubMed ID: 16406993
[TBL] [Abstract][Full Text] [Related]
13. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
[TBL] [Abstract][Full Text] [Related]
14. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
15. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
16. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification of high-grade prostate cancer treated with antegrade radical prostatectomy with intended wide resection.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Tsukamoto T; Ohkubo Y; Komai Y; Ishikawa Y; Fukui I
Jpn J Clin Oncol; 2009 Jun; 39(6):387-93. PubMed ID: 19395463
[TBL] [Abstract][Full Text] [Related]
18. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
Whittemore DE; Hick EJ; Carter MR; Moul JW; Miranda-Sousa AJ; Sexton WJ
J Urol; 2008 Feb; 179(2):516-22; discussion 522. PubMed ID: 18076949
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
Jaggi M; Johansson SL; Baker JJ; Smith LM; Galich A; Balaji KC
Urol Oncol; 2005; 23(6):402-6. PubMed ID: 16301117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
